Sandoz signs agreement with Shionogi & Co Ltd for commercialisation of Rizmoic® (naldemedine)

hand shake showing commercialisation of Rizmoic

Sandoz has signed an agreement with Shionogi & Co Ltd for commercialisation of Rizmoic® (naldemedine) in the UK.

Rizmoic®, a once-daily 200-microgram oral tablet discovered and developed by Shionogi, is an innovative medicine indicated to treat opioid induced constipation (OIC) in adult patients previously treated with a laxative.

Shionogi announced on February 22, 2019 that it had received EU marketing authorisation for Rizmoic®.

OIC is a prevalent and distressing side-effect of opioid therapy that does not respond reliably to treatment with conventional laxatives.

Under the terms of the agreement, Sandoz will be responsible for commercialising Rizmoic® in Germany, the UK and the Netherlands and Shionogi will be responsible for its manufacturing and development.

“This is a particularly unpleasant side-effect of opioid therapy, leading to great discomfort for patients who are already being treated for significant pain. I think many patients in the UK could benefit from this medicine” said Dr Josephine Heaton, Medical Director for Sandoz UK.